Protagonist Therapeutics FY Conference Summary Company Overview - **Company**: Protagonist Therapeutics (NasdaqGM:PTGX) - **Focus**: Peptide therapeutics with a transition from a platform company to commercialization through partnerships with J&J and Takeda [3][4] Key Points Current Position and Strategy - Protagonist has achieved financial independence, allowing it to fund future efforts without diluting shareholders [4] - The company emphasizes differentiation in its drug development, focusing on unmet needs [4] Product Pipeline - **Iko (oral IL-23 blocker)**: - First-in-class oral IL-23 blocker with a strong safety profile, described as having placebo-like safety [6][7] - Expected to dominate the psoriasis market due to its unique oral formulation and proven efficacy [7][10] - Clinical data shows over 70% of patients achieving significant skin clearance in 16 weeks [9] - Market research indicates a potential shift from injectables to oral options, with 75%-90% of injectable patients willing to switch [10] - Estimated market potential for Iko is around $10 billion to $12 billion, with competitors like Skyrizi moving towards $20 billion [14] - **Psoriatic Arthritis**: - Market size is smaller compared to psoriasis and IBD, estimated at 10%-15% of the total market [16] - Success in psoriasis is expected to translate to psoriatic arthritis, with a 100% success rate observed in IL-23 blockers [15] - **Inflammatory Bowel Disease (IBD)**: - Phase II data shows 30% clinical remission in ulcerative colitis (UC) patients, indicating strong potential [17][18] - The drug targets overexpressed receptors in GI tissues, which may enhance efficacy [18] - The company plans to include both biologic-naive and experienced patients in Phase III studies [19] - **Rusfertide**: - A first-in-class treatment for polycythemia vera (PV), with priority review status expected to lead to potential approvals [28] - Estimated peak sales opportunity of $1 billion to $2 billion, with a focus on addressing uncontrolled hematocrit levels [30][33] - The U.S. prevalence of PV is around 150,000-160,000 patients, with 80,000-100,000 currently on treatment [33] Financial Considerations - Protagonist has opted out of certain partnership agreements to retain a higher percentage of revenue, with a royalty structure of 21% up to $1.5 billion in net sales and 29% beyond that [41][42] - The company is considering share buybacks to return value to shareholders, emphasizing its strong cash flow and R&D pipeline [53] Future Directions - Protagonist is open to exploring partnerships for larger indications while maintaining independence for smaller ones [46] - The company is expanding its research capabilities beyond peptides, including small molecules and oligonucleotides, to address unmet needs [57] Additional Insights - The company believes that the current market dynamics and its innovative pipeline position it well for future growth, despite market volatility [53] - Protagonist's strategy includes leveraging partnerships for commercialization while focusing on its core competencies in drug development [46][47]